Use of gp130 activators in diabetic neuropathy
View Patent ↗The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
1. A method for treating diabetic neuropathy, comprising administering an effective amount of a substance signalling through gp130 to a patient in need thereof, wherein said substance is:
a) interleukin-6 (IL-6);
b) a fragment of a) which binds to gp80 and initiates signaling through gp130;
c) a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130; or
d) a salt or functional derivative of a), b) or c) which initiates signaling through gp130 .
2. A method according to claim 1 , wherein the functional derivative comprises at least one moiety attached to one or more functional groups which occur as one or more side chains on the amino acid residues.
3. A method according to claim 2 , wherein the moiety is a polyethylene moiety.
4. A method according to claim 1 , wherein the substance signaling through gp130 is administered in an amount ranging from about 0.1 to 1000 μg/kg.
5. A method according to claim 4 , wherein the substance signaling through gp130 is administered in an amount of about 1 μg/kg or 3 μg/kg or 10 μg/kg or 30 μg/kg.
6. A method according to claim 4 , wherein the substance signaling through gp130 is used in an amount ranging from about 1 to 500 μg/kg.
7. A method according to claim 4 , wherein the substance signaling through gp130 is administered in an amount ranging from about 0.1 to 100 μg/kg.
8. A method according to claim 1 , wherein the substance signaling through gp130 is administered daily.
9. A method according to claim 1 , wherein the substance signaling through gp130 is administered three times per week.
10. A method according to claim 1 , wherein the substance signaling through gp130 is administered once a week.
11. A method according to claim 1 , wherein the diabetic neuropathy is a polyneuropathy.
12. A method according to claim 1 , wherein the diabetic neuropathy is a mononeuropathy.
13. A method according to claim 1 , wherein the substance is glycosylated at one or more sites.
14. A method according to claim 1 , wherein the substance is not glycosylated.
15. A method in accordance with claim 1 , wherein said substance is IL-6.
16. A method in accordance with claim 15 , wherein said IL-6 is administered in an amount of about 1, 3, 10 or 30 μg/kg.
17. A method according to claim 15 , wherein said IL-6 is recombinant IL-6.